Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy.

@article{Fox2010TumorNF,
  title={Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy.},
  author={Norma Lynn Fox and Robin Humphreys and Troy A. Luster and Jerry E. Klein and Gilles Gallant},
  journal={Expert opinion on biological therapy},
  year={2010},
  volume={10 1},
  pages={1-18}
}
IMPORTANCE OF THE FIELD Agents that activate the TNF-related apoptosis-inducing ligand death receptors, TRAIL-R1 and TRAIL-R2, have attracted substantial attention and investment as potential anti-cancer therapies. Preclinical studies of TRAIL-R agonists indicate that they may be efficacious in a wide range of tumor types, especially when combined with chemotherapeutic agents. AREAS COVERED IN THIS REVIEW The rationale for clinical development of TRAIL-R agonists is described, including the… CONTINUE READING

From This Paper

Topics from this paper.
24 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Similar Papers

Loading similar papers…